

Yvonne Naegelin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3025117/publications.pdf>

Version: 2024-02-01

65
papers

3,870
citations

172457

29
h-index

128289

60
g-index

66
all docs

66
docs citations

66
times ranked

5803
citing authors

#	ARTICLE	IF	CITATIONS
1	Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients. <i>Cerebellum</i> , 2022, 21, 632-646.	2.5	8
2	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. <i>Lancet Neurology</i> , The, 2022, 21, 246-257.	10.2	210
3	Changes in the Cerebrospinal Fluid and Plasma Lipidome in Patients with Rett Syndrome. <i>Metabolites</i> , 2022, 12, 291.	2.9	14
4	Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019. <i>Annals of Neurology</i> , 2021, 89, 610-616.	5.3	68
5	Classification of multiple sclerosis based on patterns of <scp>CNS</scp> regional atrophy covariance. <i>Human Brain Mapping</i> , 2021, 42, 2399-2415.	3.6	10
6	Practice Effects of Mobile Tests of Cognition, Dexterity, and Mobility on Patients With Multiple Sclerosis: Data Analysis of a Smartphone-Based Observational Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e30394.	4.3	21
7	Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 90, 477-489.	5.3	16
8	Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort. <i>European Journal of Neurology</i> , 2021, 28, 4153-4166.	3.3	10
9	Fingolimod in children with Rett syndrome: the FINGORETT study. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 19.	2.7	12
10	New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis. <i>Journal of Neurology</i> , 2020, 267, 192-202.	3.6	12
11	Levels of brain-derived neurotrophic factor in patients with multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2251-2261.	3.7	23
12	Growth differentiation factor 15 is increased in stable MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	12
13	Longitudinal patterns of cortical thinning in multiple sclerosis. <i>Human Brain Mapping</i> , 2020, 41, 2198-2215.	3.6	26
14	Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis. <i>Journal of Neurology</i> , 2020, 267, 1536-1546.	3.6	35
15	Monitoring of radiologic disease activity by serum neurofilaments in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	24
16	Preferential spinal cord volume loss in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 947-957.	3.0	44
17	Plasma proteome in multiple sclerosis disease progression. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1582-1594.	3.7	21
18	Accurate, rapid and reliable, fully automated MRI brainstem segmentation for application in multiple sclerosis and neurodegenerative diseases. <i>Human Brain Mapping</i> , 2019, 40, 4091-4104.	3.6	22

#	ARTICLE	IF	CITATIONS
19	Cerebrospinal fluid from Alzheimer's disease patients promotes tau aggregation in transgenic mice. <i>Acta Neuropathologica Communications</i> , 2019, 7, 72.	5.2	16
20	Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis. <i>JAMA Neurology</i> , 2019, 76, 274.	9.0	56
21	SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1485-1498.	3.0	19
22	Measuring and Validating the Levels of Brain-Derived Neurotrophic Factor in Human Serum. <i>ENeuro</i> , 2018, 5, ENEURO.0419-17.2018.	1.9	95
23	Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis. <i>European Neurology</i> , 2018, 80, 207-214.	1.4	5
24	Spinal cord volume loss. <i>Neurology</i> , 2018, 91, e349-e358.	1.1	66
25	Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 14-20.	2.0	13
26	Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. <i>Brain</i> , 2018, 141, 2382-2391.	7.6	345
27	Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. <i>Annals of Neurology</i> , 2017, 81, 857-870.	5.3	768
28	Multiple Sclerosis: Associations Between Physical Disability and Depression Are Not Mediated by Self-Reported Physical Activity. <i>Perceptual and Motor Skills</i> , 2017, 124, 974-991.	1.3	4
29	Clinical studies and anti-inflammatory mechanisms of treatments. <i>Epilepsia</i> , 2017, 58, 69-82.	5.1	34
30	Individual Assessment of Brain Tissue Changes in MS and the Effect of Focal Lesions on Short-Term Focal Atrophy Development in MS: A Voxel-Guided Morphometry Study. <i>International Journal of Molecular Sciences</i> , 2016, 17, 489.	4.1	11
31	Efficacy and Safety of Fingolimod in an Unselected Patient Population. <i>PLoS ONE</i> , 2016, 11, e0146190.	2.5	18
32	Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial). <i>Journal of Neurology</i> , 2016, 263, 1364-1374.	3.6	13
33	Fluctuations of spontaneous EEG topographies predict disease state in relapsing-remitting multiple sclerosis. <i>NeuroImage: Clinical</i> , 2016, 12, 466-477.	2.7	78
34	Switching from natalizumab to fingolimod. <i>Neurology</i> , 2015, 85, 29-39.	1.1	110
35	Comparison between balanced steady-state free precession and standard spoiled gradient echo magnetization transfer ratio imaging in multiple sclerosis: methodical and clinical considerations. <i>NeuroImage</i> , 2015, 108, 87-94.	4.2	6
36	Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2015, 262, 1909-1917.	3.6	18

#	ARTICLE	IF	CITATIONS
37	Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 410-418.	1.9	111
38	Progression in disability and regional grey matter atrophy in relapsing—remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 202-213.	3.0	30
39	Label—fusion—segmentation and deformation—based shape analysis of deep gray matter in multiple sclerosis: The impact of thalamic subnuclei on disability. <i>Human Brain Mapping</i> , 2014, 35, 4193-4203.	3.6	34
40	Improved Characterization of Visual Evoked Potentials in Multiple Sclerosis by Topographic Analysis. <i>Brain Topography</i> , 2014, 27, 318-327.	1.8	15
41	MRI characteristics of periaqueductal lesions in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 542-551.	2.0	13
42	The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2014, 20, 356-364.	3.0	76
43	Atorvastatin Added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial. <i>PLoS ONE</i> , 2014, 9, e86663.	2.5	31
44	Cerebellar Abnormalities Contribute to Disability Including Cognitive Impairment in Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e86916.	2.5	73
45	Glutamate gene polymorphisms predict brain volumes in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 281-288.	3.0	20
46	Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration. <i>European Journal of Radiology</i> , 2013, 82, e848-e852.	2.6	12
47	Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1290-1296.	3.0	103
48	Utility of neuropsychological testing for guiding treatment decisions in paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 366-368.	3.0	2
49	Relevance of Spinal Cord Abnormalities to Clinical Disability in Multiple Sclerosis: MR Imaging Findings in a Large Cohort of Patients. <i>Radiology</i> , 2013, 269, 542-552.	7.3	52
50	Spatiotemporal distribution of white matter lesions in relapsing—remitting and secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1577-1584.	3.0	26
51	Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial. <i>Journal of Neurology</i> , 2012, 259, 2401-2413.	3.6	37
52	Evaluation of a new approach for semi-automatic segmentation of the cerebellum in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2012, 259, 2673-2680.	3.6	27
53	3D GRASE arterial spin labelling reveals an inverse correlation of cortical perfusion with the white matter lesion volume in MS. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1570-1576.	3.0	29
54	Multivariate pattern classification of gray matter pathology in multiple sclerosis. <i>NeuroImage</i> , 2012, 60, 400-408.	4.2	47

#	ARTICLE	IF	CITATIONS
55	Biplanar MRI for the assessment of the spinal cord in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1560-1569.	3.0	82
56	Longitudinal gray matter changes in multiple sclerosisâ€”Differential scanner and overall diseaseâ€”related effects. <i>Human Brain Mapping</i> , 2012, 33, 1225-1245.	3.6	40
57	Clinical EEG in cognitively impaired patients with Parkinson's Disease. <i>Journal of the Neurological Sciences</i> , 2011, 310, 75-78.	0.6	17
58	Effect of immunomodulatory medication on regional gray matter loss in relapsingâ€”remitting multiple sclerosisâ€”A longitudinal MRI study. <i>Brain Research</i> , 2010, 1325, 174-182.	2.2	31
59	Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsingâ€”remitting multiple sclerosis. <i>Human Brain Mapping</i> , 2010, 31, 1542-1555.	3.6	42
60	Acute Vertigo with Double Vision â€” Brainstem Stroke or Stroke Mimic?. <i>Cerebrovascular Diseases</i> , 2010, 30, 626-627.	1.7	3
61	Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. <i>Human Molecular Genetics</i> , 2009, 18, 767-778.	2.9	419
62	Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis â€” A longitudinal voxel-based morphometry study. <i>NeuroImage</i> , 2009, 45, 60-67.	4.2	83
63	Intravenous levetiracetam: Treatment experience with the first 50 critically ill patients. <i>Epilepsy and Behavior</i> , 2008, 12, 477-480.	1.7	102
64	Non-communicating syringomyelia: a feature of spinal cord involvement in multiple sclerosis. <i>Brain</i> , 2008, 131, 1776-1782.	7.6	18
65	Beta Activity in Status Epilepticus. <i>Epilepsia</i> , 2006, 47, 207-210.	5.1	30